阿德福韦酯和拉米夫定联合治疗肝炎后肝硬化的效果及安全性分析

Abstract
Figure/Table
References (15)
Related Citation (4)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo study the curative effects of Adefovir ester(ADV)joint Lamivudine (LAM)and Entecavir (ETV)monotherapy in patients with cirrhosis after hepatitis.Methods120 cases who had hepatitis B cirrhosis treated in our hospital between December 2012 to October 2015 were seleeted,they were randomly divided into control group and observation group,with 60 cases in each group,patients of two groups were given conventional support treatment,control group was given Entecavir treatment,the treatment group was given Adefovir ester joint Lamivudine treatment,after 1 month,2 months,6 months,1 year treatment,hepatitis B virus DNA(HBV DNA)turn rate and hepatitis B e antigen (HBeAg)serological conversion rate of two groups were compared,before and 1 year after treatment Child-Pugh score,albumin(propagated),total bilirubin(TBiL),alanine aminotransferase(ALT),prothrombin activity(PTA)level,and the presence of adverse reactions after treatment of two groups were compard.ResultsTwo groups of patients in the treatment of 1 month to 1 year was compared with HBV-DNA overcast rate,HBeAg serological conversion rates,there was no statistically significant difference (P＞0.05);before treatment and after 1 year of therapy,ALT,TBiL level,Child scores of the two groups were significantly lower,PTA level increased significantly,the difference was statistically significant(P＜0.05).1 year after treatment,the incidence of adverse reactions in patients with similar between the two groups had no statistical significance(P＞0.05).ConclusionAdefovir ester and Lamivudine combination therapy of hepatitis B cirrhosis of the liver curative effect is distinct,and safe and worthy of clinical promotion.

Key words： Adefovir ester Lamivudine Entecavir Hepatitis B cirrhosis of the live

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PAN Ai-huan
	GUO Rui-hua
	LAO Cheng-kang

Cite this article:

PAN Ai-huan,GUO Rui-hua,LAO Cheng-kang. Adefovir ester and Lamivudine combination therapy after hepatitis cirrhosis of the liver efficacy and safety analysis[J]. 中国当代医药, 2017, 24(15): 79-81.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I15/79

[1]	Yuen MF，Ahn SH，Lee KS，et al.Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs.entecavir∶results from a multicentre study[J].J Hepatol，2015，62（3）：526-532.
[2]	中华医学会肝病学分会、中华医学会感染病学分会.慢性乙型肝炎防治指南（2015年版）[J].中华实验和临床感染病杂志：电子版，2015，9（5）：570-589.
[3]	窦爱华，徐斌.失代偿期乙型肝炎肝硬化患者三种抗病毒方案长期随访疗效比较[J].中国全科医学，2014，（34）：4097-4100.
[4]	Liu L，Yan Y，Zhou J，et al.Curative effect of combined lamivudine adefovir dipivoxil，and stem cell transplantation on decompensated hepatitis B cirrhosis[J].Genet Mol Res，2014，13（4）：9336-9342.
[5]	WHO.Guidelines for the prevention，care and treatment of persons with chronic hepatitis B infection[R].Geneva Switzerland：World Health Organization，May 12，2015.
[6]	Terrault N A，Bzowej N H，Chang KM，et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology，2016，63（2）：261-283.
[7]	邓秋飒.阿德福韦酯联合拉米夫定与恩替卡韦单药治疗乙肝肝硬化疗效差异分析[J].中国现代药物应用，2015，9（11）：49-50.
[8]	吕巍巍，贾鹏.探讨阿德福韦酯联合拉米夫定与恩替卡韦单药治疗乙肝肝硬化的疗效.临床医药文献杂志，2016，3（8）：1548-1549.
[9]	陈开革，梁敏燕.阿德福韦酯联合拉米夫定与单纯恩替卡韦对乙肝患者抗病毒效果的对比分析[J].医学研究杂志，2014，43（9）：146-148.
[11]	赵子龙.阿德福韦酯联合拉米夫定与恩替卡韦单药治疗乙肝肝硬化疗效比较[J].现代中西医结合杂志，2016，25（33）：3716-3718.
[12]	孙建民.拉米夫定联合阿德福韦酯与恩替卡韦单药治疗失代偿期乙型肝炎肝硬化的疗效比较[J].中国临床实用医学，2015，16（2）：56-57.
[13]	段树鹏，朱利红.不同核苷类抗病毒药物用于乙肝肝硬化的对比分析[J].中国继续医学教育，2015，7（12）：163-164.
[14]	魏兆勇，张分明，许德军，等.拉米夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化临床观察[J].中华医院感染学杂志，2014，24（2）：361-363.
[15]	曹玉华.联用阿德福韦酯和拉米夫定与单用恩替卡韦治疗乙肝肝硬化的疗效对比分析[J].当代医药论丛，2014，15（7）：548-549.
[10]	Woo HY，Choi JY，Yoon SK，et al.Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus[J].Clin Mol Hepatol，2014，20（2）：168-176.